{"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}],"groups":[{"description":"Ixazomib 3 mg, capsules, orally, twice-weekly on Days 1, 4, 8, and 11, lenalidomide 25 mg, capsules, orally, once daily on Days 1-14, dexamethasone 20 mg, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 in Cycle 1-8 and dexamethasone 10 mg, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 in Cycle 9-16 in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly on Days 1, 4, 8, and 11 in 21-day treatment cycles as maintenance therapy at the dose tolerated at the end of induction until progressive disease or unacceptable toxicity. The maximum number of cycles received was 83 cycles (approximately up to 2037 days).","id":"BG000","title":"Phase 1: Ixazomib 3 mg"},{"description":"Ixazomib (MLN9708) 3.7 mg, capsules, orally, twice-weekly on Days 1, 4, 8, and 11, lenalidomide 25 mg, capsules, orally, once daily on Days 1-14, dexamethasone 20 mg, capsules, orally, once daily on days 1, 2, 4, 5, 8, 9, 11, and 12 in Cycle 1-8 and dexamethasone 10 mg, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 in Cycle 9-16 in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly on Days 1, 4, 8, and 11 in 21-day treatment cycles as maintenance therapy at the dose tolerated at the end of induction until progressive disease or unacceptable toxicity. The maximum number of cycles received in this cohort was 25 cycles (approximately 585 days).","id":"BG001","title":"Phase 1: Ixazomib 3.7 mg"},{"description":"Ixazomib 3 mg (MLN9708), capsules, orally, twice-weekly on Days 1, 4, 8, and 11, lenalidomide 25 mg capsules, orally, once daily on Days 1-14, dexamethasone 20 mg, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 in Cycle 1-8 and dexamethasone 10 mg, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 in Cycle 9-16 in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 2. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly on Days 1, 4, 8, and 11 in 21-day treatment cycles as maintenance therapy at the dose tolerated at the end of induction until progressive disease or unacceptable toxicity. The maximum number of cycles received in this cohort was 74 cycles (approximately 1875 days).","id":"BG002","title":"Phase 2: Ixazomib 3 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.04","value":"64.3"},{"groupId":"BG001","spread":"6.20","value":"61.1"},{"groupId":"BG002","spread":"10.03","value":"61.5"},{"groupId":"BG003","spread":"9.82","value":"61.8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"24"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"40"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"48"},{"groupId":"BG003","value":"62"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"54"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.09","value":"171.1"},{"groupId":"BG001","spread":"7.10","value":"170.9"},{"groupId":"BG002","spread":"9.30","value":"171.2"},{"groupId":"BG003","spread":"9.43","value":"171.1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"49"},{"groupId":"BG003","value":"62"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"For this baseline measure, number of participants evaluable were 7, 6 and 49 for each arm, respectively.","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"17.083","value":"94.29"},{"groupId":"BG001","spread":"19.295","value":"82.56"},{"groupId":"BG002","spread":"16.701","value":"81.22"},{"groupId":"BG003","spread":"17.228","value":"82.80"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.2192","value":"2.109"},{"groupId":"BG001","spread":"0.2657","value":"1.960"},{"groupId":"BG002","spread":"0.2373","value":"1.958"},{"groupId":"BG003","spread":"0.2390","value":"1.975"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"49"},{"groupId":"BG003","value":"62"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"For this baseline measure, number of participants evaluable were 7, 6 and 49 for each arm, respectively.","title":"Body Surface Area (BSA)","unitOfMeasure":"m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"29"}],"title":"IgG Kappa"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"9"}],"title":"IgG Lambda"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"12"}],"title":"IgA Kappa"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"}],"title":"IgA Lambda"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Biclonal"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"}],"title":"Lambda Free Light Chains"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}],"title":"Kappa Free Light Chains"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"description":"Types of Myeloma was described on the basis of antibodies produced by cancerous plasma cells.","paramType":"COUNT_OF_PARTICIPANTS","title":"Type of Myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"35"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"26"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"}],"title":"2"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"description":"ECOG performance status is used to assess how the disease affects the daily living abilities of the participant. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for less than (\\<) 50 percent (%) of the time; 3= in bed for greater than (\\>) 50% of the time; 4= 100% bedridden; 5= dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"title":"Less than or equal to (<=) 2 mg/dL"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Greater than (>) 2 mg/dL"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Serum Creatinine Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"12"}],"title":"30 - 60 mL/min"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"52"}],"title":">60 mL/min"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Creatinine Clearance Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.275","value":"9.83"},{"groupId":"BG001","spread":"0.561","value":"9.79"},{"groupId":"BG002","spread":"0.617","value":"10.01"},{"groupId":"BG003","spread":"0.583","value":"9.96"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"description":"Corrected calcium was calculated using the following formula: serum calcium (mg/dL)+0.98\\*\\[4-serum albumin (gram per deciliter \\[g/dL\\])\\]","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Corrected Calcium","unitOfMeasure":"mg/dL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"21.59","value":"103.4"},{"groupId":"BG001","spread":"16.42","value":"112.0"},{"groupId":"BG002","spread":"14.36","value":"108.9"},{"groupId":"BG003","spread":"15.32","value":"108.6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Hemoglobin","unitOfMeasure":"gram per liter (g/L)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"45"}],"title":"Present"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"10"}],"title":"Not Present"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Indeterminate"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"8"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Participants with Lytic Bone Lesions Present","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"20"}],"title":"Plasmacytomas Present"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"8"}],"title":"Plasmacytomas Not Present"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"36"}],"title":"Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"64"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who performed magnetic resonance imaging (MRI)/computed tomography (CT) scan were eligible for this baseline measure.","title":"Participants with Extramedullary Plasmacytomas","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included all participants who received at least 1 dose of any study drug."}